Physician profile
Rouba Garro
NPI 1427380542
$9,146.85
in general payments reported to CMS, 2019-2025
7 companies · $2,240 in 2025
The $2,240 reported for 2025 was more than what 83% of Pediatric Nephrology providers received nationally (typical 2025 total: $131).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1.31 · 2021: $3.82 · 2022: $21.17 · 2023: $248 · 2024: $6,633 · 2025: $2,240.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $5,895 · Travel and Lodging: $2,288 · Food and Beverage: $937.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $5,895.00 |
| Travel and Lodging | $2,288.13 |
| Food and Beverage | $937.42 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $6,592.70 | 2024 | Procysbi |
| Merck Sharp & Dohme LLC | $1,570.14 | 2025 | Prevymis |
| Alexion Pharmaceuticals, INC. | $812.50 | 2023-2025 | Ultomiris, Soliris |
| Alnylam Pharmaceuticals INC. | $105.15 | 2023 | Oxlumo |
| Takeda Pharmaceuticals U.S.A., INC. | $40.06 | 2024 | Livtencity |
| Novartis Pharmaceuticals Corporation | $21.17 | 2022 | |
| Travere Therapeutics, INC. | $5.13 | 2019-2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Rouba Garro listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.